US Patent 5,965,530: Claims, Validity Pressure Points, and US Landscape

What is US 5,965,530 and what do its claims cover?

US 5,965,530 is a granted US utility patent (issued Oct. 12, 1999) with an asserted priority that traces to an earlier application filing in the 1990s. The patent’s claim set defines a defined technical scope around a specific class of compositions and/or methods (the “invention” as the examiner allowed and the patentee later relied on).

Critical limitation for landscape work: a reliable claim-by-claim and limitation-by-limitation analysis requires the exact claim text and independent/dependent structure. The record necessary for that (the full claims as published in the issued patent) is not present in the materials available in this chat. Without the exact claim language, any attempt to describe coverage (what is claimed, what limitations exist, and what the claim elements require) would be speculative, which fails an accuracy standard for a patent landscape deliverable.

What are the claim-construction and validity pressure points in the US system?

Absent the verbatim claim set, the only safe analysis is structural: how US courts and PTAB panels typically evaluate the kinds of claims that tend to be granted in 1990s-era utility filings, and where those claims usually face attack in US validity proceedings.

Likely invalidity axes used against patents of this type (typical US patterns)

Anticipation under 35 USC 102
- Examiners and litigators often focus on whether a single prior-art reference discloses every claim limitation.
- For multi-parameter inventions, a single reference rarely discloses the full combination unless it is a close match product or process.
Obviousness under 35 USC 103
- Common failure mode is a claim that recites a known feature plus another known feature with a predictable result.
- Obviousness attacks frequently argue that a person of ordinary skill would combine teachings, especially if the patent’s specification cites general knowledge and common substitutions.
Indefiniteness under 35 USC 112(b)
- Broad functional language (if present) is often attacked for failing to define the metes and bounds with reasonable certainty.
- “Result” or “effect” driven limitations often trigger indefiniteness if they do not tie to measurable structure or steps.
Enablement and written description under 35 USC 112(a)
- If the patent contains broad generic ranges but only examples for narrow subsets, enablement and written description attacks can succeed.
- Software or process claims (if any) are often evaluated for whether the patent describes enough detail to perform without undue experimentation.
Subject-matter eligibility under 35 USC 101
- For 1999-era technology, 101 issues vary by field. If the claims are method claims tied to conventional steps without additional technical transformation, they can face eligibility pressure.
- If claims are purely on abstract ideas without a technical contribution, 101 becomes a risk factor.

What this means for US 5,965,530: to translate these axes into a real “pressure map,” the claim language must be known. Otherwise, the analysis cannot identify which limitation(s) are missing from prior art, which dependent claims are actually narrower, or which claim phrases likely invite construction disputes.

How does the US patent landscape evaluate competitive risk around 5,965,530?

A proper landscape for a single US patent usually tracks:

Citation neighborhood: patents and non-patent literature most relevant to the independent claim elements.
Same-family continuation activity: whether the patentee expanded scope in continuations or divisionals.
Family member enforcement: whether the patent was asserted or settled, creating prosecution-history estoppel or signal about scope.
PTAB events: inter partes review (IPR), post-grant review, ex parte reexamination, and appeal history.
Design-around surface: later patents that omit specific claim limitations while pursuing the same market goals.

Landscape constraint: None of the above can be executed accurately without the actual bibliographic and prosecution record (claims, CPC/IPC classification, inventor/assignee, continuations, family members, and the actual cited prior art). Those data are not present here.

What prior art likely matters under 102/103 for US 5,965,530?

Without the claim text, the only defensible statement is process-based:

For a late-1990s US patent, the most relevant prior art typically comes from:
- US applications and patents published in the early to mid-1990s
- Non-patent literature in the same timeframe (journal articles, conference proceedings)
- Standard references already recognized in that field prior to the filing date
If the claims cover a specific formulation, composition, or parameter range, the prior art search usually narrows to:
- The “closest disclosed” compositions and processes
- Ranges and substitutions that align with the claimed parameters
- Any teaching on stability, efficacy, or manufacturing that matches the claimed effect

But the search terms, the precise limitation matching, and the “closest prior art” identification must be keyed off the actual claim language and specification.

Does the patent face PTAB challenges and where would they concentrate?

PTAB post-grant challenges typically concentrate on:

Independent claims (highest leverage in invalidating enforceability)
Weak dependent claims that rely on the independent claim’s broadest limitation
Most-cited prior art used during prosecution, because it often appears again in later art challenges

However: whether US 5,965,530 has faced PTAB review, and which claims were attacked, requires the event record for this specific patent and is not available in this chat.

What is the enforcement and commercial relevance signal for the patent?

Real-world landscape relevance usually shows up via:

Litigation dockets (district court filings, ITC matters)
License and settlement agreements
Continued product development around the claim’s core teaching

This evidence set cannot be generated for US 5,965,530 without access to enforcement data in the prompt context.

Decision-grade summary

A comprehensive and critical analysis of the claims and a US patent landscape for US 5,965,530 requires the issued claim text, bibliographic data, and the cited-reference record. These are not included in the available input for this task.

Under the accuracy constraint for a patent analyst, producing a claim-by-claim coverage map, identifying specific prior art that anticipates or renders the claims obvious, or listing specific competing patents would be speculative.

Key Takeaways

US 5,965,530 analysis at decision-grade resolution requires the exact issued claim language and prosecution/prior-art record, which are not provided here.
Without the claims and citation neighborhood, any purported “critical analysis” of novelty (102), obviousness (103), or eligibility (101) would not meet the required accuracy standard.
A real landscape must enumerate nearby patents and events (continuations, PTAB challenges, enforcement) keyed to claim elements; none of that can be generated reliably from the current record.

FAQs

What does a decision-grade claim analysis require?
The issued claim text (independent and dependent structure), key limitation phrases, and the prosecution history that shaped those limitations.
What makes a patent landscape “critical” instead of descriptive?
It must identify specific claim elements, match them to specific prior art disclosures, and quantify overlap risk (anticipation vs. combination obviousness).
Where do validity challenges typically focus in US patents?
They typically target independent claims and the most pivotal limitations, then leverage dependent claims’ dependency structure.
What signals whether a patent is landscape-relevant to competitors?
PTAB events, litigation/enforcement, and continuations that show the patentee’s confidence in claim scope.
Can landscape mapping be done without the claim text?
Not at the level required for investment or R&D decisions; claim element matching is the core of the method.

References

[1] USPTO, United States Patent 5,965,530 (Issued Oct. 12, 1999). (Not available in provided prompt context.)

Title:	Therapeutic uses of keratinocyte growth factor
Abstract:	Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF in vivo enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.
Inventor(s):	Glenn Francis Pierce, Regina Mae Housley, Charles Frederick Morris
Assignee:	Swedish Orphan Biovitrum AB
Application Number:	US08/484,068
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 5,965,530: Claims, Validity Pressure Points, and US Landscape What is US 5,965,530 and what do its claims cover? US 5,965,530 is a granted US utility patent (issued Oct. 12, 1999) with an asserted priority that traces to an earlier application filing in the 1990s. The patent’s claim set defines a defined technical scope around a specific class of compositions and/or methods (the “invention” as the examiner allowed and the patentee later relied on). Critical limitation for landscape work: a reliable claim-by-claim and limitation-by-limitation analysis requires the exact claim text and independent/dependent structure. The record necessary for that (the full claims as published in the issued patent) is not present in the materials available in this chat. Without the exact claim language, any attempt to describe coverage (what is claimed, what limitations exist, and what the claim elements require) would be speculative, which fails an accuracy standard for a patent landscape deliverable. What are the claim-construction and validity pressure points in the US system? Absent the verbatim claim set, the only safe analysis is structural: how US courts and PTAB panels typically evaluate the kinds of claims that tend to be granted in 1990s-era utility filings, and where those claims usually face attack in US validity proceedings. Likely invalidity axes used against patents of this type (typical US patterns) Anticipation under 35 USC 102 Examiners and litigators often focus on whether a single prior-art reference discloses every claim limitation. For multi-parameter inventions, a single reference rarely discloses the full combination unless it is a close match product or process. Obviousness under 35 USC 103 Common failure mode is a claim that recites a known feature plus another known feature with a predictable result. Obviousness attacks frequently argue that a person of ordinary skill would combine teachings, especially if the patent’s specification cites general knowledge and common substitutions. Indefiniteness under 35 USC 112(b) Broad functional language (if present) is often attacked for failing to define the metes and bounds with reasonable certainty. “Result” or “effect” driven limitations often trigger indefiniteness if they do not tie to measurable structure or steps. Enablement and written description under 35 USC 112(a) If the patent contains broad generic ranges but only examples for narrow subsets, enablement and written description attacks can succeed. Software or process claims (if any) are often evaluated for whether the patent describes enough detail to perform without undue experimentation. Subject-matter eligibility under 35 USC 101 For 1999-era technology, 101 issues vary by field. If the claims are method claims tied to conventional steps without additional technical transformation, they can face eligibility pressure. If claims are purely on abstract ideas without a technical contribution, 101 becomes a risk factor. What this means for US 5,965,530: to translate these axes into a real “pressure map,” the claim language must be known. Otherwise, the analysis cannot identify which limitation(s) are missing from prior art, which dependent claims are actually narrower, or which claim phrases likely invite construction disputes. How does the US patent landscape evaluate competitive risk around 5,965,530? A proper landscape for a single US patent usually tracks: Citation neighborhood: patents and non-patent literature most relevant to the independent claim elements. Same-family continuation activity: whether the patentee expanded scope in continuations or divisionals. Family member enforcement: whether the patent was asserted or settled, creating prosecution-history estoppel or signal about scope. PTAB events: inter partes review (IPR), post-grant review, ex parte reexamination, and appeal history. Design-around surface: later patents that omit specific claim limitations while pursuing the same market goals. Landscape constraint: None of the above can be executed accurately without the actual bibliographic and prosecution record (claims, CPC/IPC classification, inventor/assignee, continuations, family members, and the actual cited prior art). Those data are not present here. What prior art likely matters under 102/103 for US 5,965,530? Without the claim text, the only defensible statement is process-based: For a late-1990s US patent, the most relevant prior art typically comes from: US applications and patents published in the early to mid-1990s Non-patent literature in the same timeframe (journal articles, conference proceedings) Standard references already recognized in that field prior to the filing date If the claims cover a specific formulation, composition, or parameter range, the prior art search usually narrows to: The “closest disclosed” compositions and processes Ranges and substitutions that align with the claimed parameters Any teaching on stability, efficacy, or manufacturing that matches the claimed effect But the search terms, the precise limitation matching, and the “closest prior art” identification must be keyed off the actual claim language and specification. Does the patent face PTAB challenges and where would they concentrate? PTAB post-grant challenges typically concentrate on: Independent claims (highest leverage in invalidating enforceability) Weak dependent claims that rely on the independent claim’s broadest limitation Most-cited prior art used during prosecution, because it often appears again in later art challenges However: whether US 5,965,530 has faced PTAB review, and which claims were attacked, requires the event record for this specific patent and is not available in this chat. What is the enforcement and commercial relevance signal for the patent? Real-world landscape relevance usually shows up via: Litigation dockets (district court filings, ITC matters) License and settlement agreements Continued product development around the claim’s core teaching This evidence set cannot be generated for US 5,965,530 without access to enforcement data in the prompt context. Decision-grade summary A comprehensive and critical analysis of the claims and a US patent landscape for US 5,965,530 requires the issued claim text, bibliographic data, and the cited-reference record. These are not included in the available input for this task. Under the accuracy constraint for a patent analyst, producing a claim-by-claim coverage map, identifying specific prior art that anticipates or renders the claims obvious, or listing specific competing patents would be speculative. Key Takeaways US 5,965,530 analysis at decision-grade resolution requires the exact issued claim language and prosecution/prior-art record, which are not provided here. Without the claims and citation neighborhood, any purported “critical analysis” of novelty (102), obviousness (103), or eligibility (101) would not meet the required accuracy standard. A real landscape must enumerate nearby patents and events (continuations, PTAB challenges, enforcement) keyed to claim elements; none of that can be generated reliably from the current record. FAQs What does a decision-grade claim analysis require? The issued claim text (independent and dependent structure), key limitation phrases, and the prosecution history that shaped those limitations. What makes a patent landscape “critical” instead of descriptive? It must identify specific claim elements, match them to specific prior art disclosures, and quantify overlap risk (anticipation vs. combination obviousness). Where do validity challenges typically focus in US patents? They typically target independent claims and the most pivotal limitations, then leverage dependent claims’ dependency structure. What signals whether a patent is landscape-relevant to competitors? PTAB events, litigation/enforcement, and continuations that show the patentee’s confidence in claim scope. Can landscape mapping be done without the claim text? Not at the level required for investment or R&D decisions; claim element matching is the core of the method. References [1] USPTO, United States Patent 5,965,530 (Issued Oct. 12, 1999). (Not available in provided prompt context.) More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KEPIVANCE	palifermin	For Injection	125103	December 15, 2004	⤷ Start Trial	2016-10-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 5,965,530

Summary for Patent: 5,965,530